Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | FPR2 | P25090 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407534 | 0.83 | ALOX5 (0.40) | MEN1KMT2AFFAR2EPHX1 | |
| SCHEMBL28819817 | 0.82 | SLC6A4 (0.40) | SLC6A4MEN1KMT2AEPHX1AKR1C3 | |
| SCHEMBL2405158 | 0.81 | ESR1 (0.41) | FFAR2EPHX1 | |
| SCHEMBL1107404 | 0.81 | AKR1C3 (0.40) | SLC6A4FPR2MEN1KMT2AAKR1C3 | |
| SCHEMBL12742235 | 0.81 | GCK (0.38) | SLC6A4MEN1KMT2AEPHX1AKR1C3 | |
| SCHEMBL2646161 | 0.81 | AKR1C3 (0.40) | SLC6A4FPR2MEN1KMT2AAKR1C3 | |
| SCHEMBL27437633 | 0.79 | EPHX1 (0.56) | MEN1KMT2AEPHX1 | |
| SCHEMBL2405258 | 0.79 | CA1 (0.42) | SLC6A4KMT2AEPHX1 | |
| SCHEMBL19331722 | 0.78 | ANPEP (0.44) | MEN1KMT2AFFAR2EPHX1 | |
| SCHEMBL2648331 | 0.78 | GCK (0.36) | SLC6A4FPR2MEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | SLC6A4 781/4885FPR2 568/4885MEN1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.